{"disease":{"id":"postmenopausal-breast-cancer","name":"postmenopausal breast cancer"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of breast cancer in postmenopausal women with hormone receptor-positive early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":58,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03401034","title":"Influence of Lifestyle, Inflammatory Biomarkers, and Genetic Factors on Long-term Breast Cancer Prognosis","phase":"","overall_status":"COMPLETED","enrollment_count":3813,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT02753686","title":"Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":440,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03572153","title":"A Mind-Body Intervention for Hot Flash Management","phase":"NA","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Baylor University","has_results":true},{"nct_id":"NCT03697200","title":"Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT02860000","title":"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03913234","title":"Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":95,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT01231659","title":"Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT00338728","title":"Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06228768","title":"Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT03236974","title":"Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02152943","title":"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01753908","title":"Broccoli Sprout Extract in Treating Patients With Breast Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03708055","title":"Weight Bearing Exercise in Preventing Frailty in Stage I-IIIA Breast Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"University of Arizona","has_results":false},{"nct_id":"NCT03128619","title":"Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03953157","title":"Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors","phase":"NA","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04493333","title":"Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"University of Arkansas","has_results":true},{"nct_id":"NCT03238703","title":"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03091842","title":"Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Southern California","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}